Mealey's (February 3, 2020, 12:15 PM EST) -- WASHINGTON, D.C. — A panel of the Federal Circuit U.S. Court of Appeals on Jan. 29 reversed and remanded a Delaware federal judge’s determination that various claims of three patents relating to the topical rosacea treatment Soolantra are invalid as anticipated (Galderma Laboratories L.P., et al. v. Teva Pharmaceuticals USA Inc., Nos. 2019-2396, 2020-1213, Fed. Cir., 2020 U.S. App. LEXIS 2811)....